H
Hiroyasu Kaneda
Researcher at Kindai University
Publications - 93
Citations - 4035
Hiroyasu Kaneda is an academic researcher from Kindai University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 31, co-authored 82 publications receiving 3195 citations.
Papers
More filters
Journal ArticleDOI
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
Koji Haratani,Hidetoshi Hayashi,Yasutaka Chiba,Keita Kudo,Kimio Yonesaka,Ryoji Kato,Hiroyasu Kaneda,Yoshikazu Hasegawa,Kaoru Tanaka,Masayuki Takeda,Kazuhiko Nakagawa +10 more
TL;DR: Development of irAEs was associated with survival outcome of nivolumab treatment in patients with advanced or recurrent NSCLC, andMultivariable analysis revealed that iraes were positively associated with Survival outcome, with hazard ratios of 0.525 and 0.282.
Journal ArticleDOI
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kazuhiko Nakagawa,Edward B Garon,Takashi Seto,Makoto Nishio,Santiago Ponce Aix,Luis Paz-Ares,Chao-Hua Chiu,Keunchil Park,Silvia Novello,Ernest Nadal,Fumio Imamura,Kiyotaka Yoh,Jin-Yuan Shih,Kwok Hung Au,Denis Moro-Sibilot,Sotaro Enatsu,Annamaria Zimmermann,Bente Frimodt-Moller,Carla Visseren-Grul,Martin Reck,Quincy Chu,Alexis B. Cortot,Jean-Louis Pujol,Elizabeth Fabre,Corinne Lamour,Helge Bischoff,Jens Kollmeier,M Kimmich,Walburga Engel-Riedel,Stefan Hammerschmidt,Wolfgang Schütte,Konstantinos N. Syrigos,James Chung-Man Ho,Kwok-Hung Au,Andrea Ardizzoni,Giulia Pasello,Vanessa Gregorc,Alessandro Del Conte,Domenico Galetta,Toshiaki Takahashi,Toru Kumagai,Katsuyuki Hotta,Yasushi Goto,Yukio Hosomi,Hiroshi Sakai,Yuichi Takiguchi,Young Hak Kim,Takayasu Kurata,Hiroyuki Yamaguchi,Haruko Daga,Isamu Okamoto,Miyako Satouchi,Satoshi Ikeda,Kazuo Kasahara,Shinji Atagi,Koichi Azuma,Keisuke Aoe,Yoshitsugu Horio,Nobuyuki Yamamoto,Hiroshi Tanaka,Satoshi Watanabe,Naoyuki Nogami,Tomohiro Ozaki,Ryo Koyama,Tomonori Hirashima,Hiroyasu Kaneda,Keisuke Tomii,Yuka Fujita,Masahiro Seike,Naoki Nishimura,Terufumi Kato,Masao Ichiki,Hideo Saka,Katsuya Hirano,Yasuharu Nakahara,Shunichi Sugawara,Sang-We Kim,Young Joo Min,Hyun Woo Lee,Jin-Hyoung Kang,Ho Jung An,Ki Hyeong Lee,Jin Soo Kim,Gyeong-Won Lee,Sung Yong Lee,A. Alexandru,Anghel Adrian Udrea,Óscar Juan-Vidal,Ernest Nadal-Alforja,Ignacio Gil-Bazo,Santiago Ponce-Aix,Belén Rubio-Viqueira,Miriam Alonso Garcia,Enriqueta Felip Font,Jose Fuentes Pradera,Juan Coves Sarto,Meng-Chih Lin,Wu Chou Su,Te Chun Hsia,Gee-Chen Chang,Yu-Feng Wei,Jian Su,Irfan Cicin,Tuncay Göksel,Hakan Harputluoglu,Ozgur Ozyilkan,Ivo Henning,Sanjay Popat,Olivia Hatcher,Kathryn Mileham,Jared Acoba,Edward B. Garon,Gabriel Jung,Moses Sundar Raj,William J. Martin,Shaker R. Dakhil +115 more
TL;DR: The RELAY trial as mentioned in this paper evaluated erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC.
Journal ArticleDOI
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
Toshiaki Takahashi,Takeharu Yamanaka,Takashi Seto,Hideyuki Harada,Hiroshi Nokihara,Hideo Saka,Makoto Nishio,Hiroyasu Kaneda,Koichi Takayama,Osamu Ishimoto,Koji Takeda,Hiroshige Yoshioka,Motoko Tachihara,Hiroshi Sakai,Koichi Goto,Nobuyuki Yamamoto +15 more
TL;DR: Prophylactic cranial irradiation is therefore not essential for patients with extensive-disease small-cell lung cancer with any response to initial chemotherapy and a confirmed absence of brain metastases when patients receive periodic MRI examination during follow-up.
Journal ArticleDOI
FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.
Hiroyasu Kaneda,Tokuzo Arao,Kaoru Tanaka,Daisuke Tamura,Keiichi Aomatsu,Kanae Kudo,Kazuko Sakai,Marco A. De Velasco,Kazuko Matsumoto,Yoshihiko Fujita,Yasuhide Yamada,Junji Tsurutani,Isamu Okamoto,Kazuhiko Nakagawa,Kazuto Nishio +14 more
TL;DR: It is found that FOXQ1 mRNA is overexpressed in clinical specimens of colorectal cancer (CRC) and enhances tumorigenicity and tumor growth presumably through its angiogenic and antiapoptotic effects.
Journal ArticleDOI
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
Junko Tanizaki,Koji Haratani,Hidetoshi Hayashi,Yasutaka Chiba,Yasushi Nakamura,Kimio Yonesaka,Keita Kudo,Hiroyasu Kaneda,Yoshikazu Hasegawa,Kaoru Tanaka,Masayuki Takeda,Akihiko Ito,Kazuhiko Nakagawa +12 more
TL;DR: A baseline signature of a low ANC, high ALC, and high AEC was associated with a better outcome of nivolumab treatment, with the number of favorable factors identifying subgroups of patients differing in survival and response rate.